Low levels of small HDL particles predict but do not influence risk of sepsis.

"our uk biobank gwas on hdl subclasses performed as part of this study is available at https://figshare com/articles/dataset/hdl_gwas/24024816 ."

"Declarations Ethics approval and consent to participateThis study was performed under the UK Biobank application number 30418. UK Biobank was ethically approved by the North West Multi-centre Research Ethics Committee (MREC). The FinnGen study is approved by the THL (Approval No. THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, and THL/1721/5.05.00/2019), the Digital and Population Data Service Agency (VRK43431/2017-3, VRK/6909/2018-3, and VRK/4415/2019-3), the Social Insurance Institution (KELA) (KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, and KELA 98/522/2019), and Statistics Finland (TK-53-1041-17). Competing interestsGDS reports Scientific Advisory Board Membership for Relation Therapeutics and Insitro. PG reports Founder and non-executive director of Fios Genomics Ltd and member of the development board of Sepsis Trust UK Ltd without renumeration. BGN reports consultancies/talks for AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, Silence Therapeutics, and Ultragenyx. FH and KMP have nothing to declare. Competing interests GDS reports Scientific Advisory Board Membership for Relation Therapeutics and Insitro. PG reports Founder and non-executive director of Fios Genomics Ltd and member of the development board of Sepsis Trust UK Ltd without renumeration. BGN reports consultancies/talks for AstraZeneca, Sanofi, Regeneron, Ionis, Amgen, Kowa, Denka, Amarin, Novartis, Novo Nordisk, Esperion, Abbott, Silence Therapeutics, and Ultragenyx. FH and KMP have nothing to declare."

"Funding FH’s time was funded by the GW4-CAT Wellcome Doctoral Fellowship Scheme. UK Biobank was funded by the Wellcome Trust, the Medical Research Council, the NIHR, and a variety of other charities (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/our-funding). FinnGen is a public–private partnership (https://www.finngen.fi/en/access_results) funded by multiple institutions across Finland. The authors want to acknowledge the participants and investigators of the FinnGen study. PGs time was funded by the Ser Cymru programme, the Welsh Government, and the EU-ERDF. FH and GDS work within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1). This research was funded in whole, or in part, by the Wellcome Trust [222894/Z/21/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission."